

BOTULINUM NEUROTOXIN TYPE A injection (Xeomin®) for chronic sialorrhoea

The Pan Mersey Area Prescribing Committee recommends the prescribing of BOTULINUM NEUROTOXIN TYPE A injection (Xeomin®) for the treatment of chronic sialorrhoea, in accordance with NICE TA605.

RED

NICE Technology Appraisal 605 recommends Xeomin® (botulinum neurotoxin type A), within its marketing authorisation, as an option for treating chronic sialorrhoea caused by neurological conditions in adults. It is recommended only if the company provides it according to the commercial arrangement.^[1]

The recommended dose per treatment session for chronic sialorrhoea is 100 units and this maximum dose should not be exceeded. Repeat treatment more frequently than every 16 weeks is not recommended.^[2]

NICE estimates the overall additional resource impact of implementing NICE TA605^[3] to be minimal (3 patients per 100,000 population) in 2019/20, rising to £25,953 per 100,000 population by 2023/24 (based on NHS list price). This includes any additional administration costs as well as additional drug costs. Resource impact will be less once the PAS discount is applied.

Prescribers are reminded that, due to unit differences in the potency assay, botulinum toxin A units are specific to the preparation and are not interchangeable from one product to another.

References

1. National Institute for Health and Care Excellence. Technology appraisal 605: [Xeomin \(botulinum neurotoxin type A\) for treating chronic sialorrhoea](#), 09 October 2019. Accessed 10 October 2019.
2. Merz Pharma UK Ltd. Summary of Product Characteristics: [Xeomin 100 units powder for solution for injection](#), 30 May 2019. Accessed 03 October 2019.
3. National Institute for Health and Care Excellence. [Resource impact template](#): Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605), October 2019. Accessed 10 October 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.